Mantle Cell Lymphoma

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Latest News

Ibrutinib Plus Chemo Induction Followed by Ibrutinib Maintenance Could Be New Standard in MCL
Ibrutinib Plus Chemo Induction Followed by Ibrutinib Maintenance Could Be New Standard in MCL

January 31st 2023

Martin Dreyling, MD, discusses the safety and efficacy data from the TRIANGLE study done in patients with previously untreated MCL who are younger than 66 years, and the impact of these results on the use of ASCT in this population.

Pirtobrutinib’s Approval Addresses Unmet Need in MCL Treatment Paradigm
Pirtobrutinib’s Approval Addresses Unmet Need in MCL Treatment Paradigm

January 31st 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

January 27th 2023

Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL
Real-World Data Highlight Underutilization of High-Dose Cytarabine/Transplant, Benefits of Maintenance Rituximab in MCL

January 24th 2023

R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients
R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients

January 16th 2023

Video Series
Video Interviews
Podcasts

More News